Menu

Search

  |   Insights & Views

Menu

  |   Insights & Views

Search

Health insurers want you to try cheaper drugs first, but that can hurt you

0
comments

Few people are familiar with the term “step therapy,” but most Americans have health insurance policies that adopt it. Step therapy programs, also known as “fail first policies,” require patients to try less expensive treatments before insurers agree to pay for more costly alternatives. Thus, insurers can deny coverage for a drug your doctor prescribed because you haven’t found other, cheaper medications to be ineffective first. As many as 75 percent of large employers have insurance plans with step therapy, and Medicare is increasingly embracing this approach as well.

My husband and I encountered step therapy when he was prescribed a new medication for his Parkinson’s disease. As a professor of law and bioethics, I have since researched and written about this phenomenon. I have found that step therapy can be sensible in some instances, but it also raises important concerns and should be carefully regulated.

Benefits and risks of step therapy

Health insurers have good reason to be worried about health care costs and to try to limit them. Medical costs have famously ballooned in recent years. According to a congressional report, “the prices of many of the most popular brand-name drugs increased at nearly ten times the cost of inflation from 2012 to 2017.” Thus, it often makes sense to require patients to try cheaper but equally effective choices, such as generic rather than brand-name drugs.

However, in some cases, step therapy can increase costs in the long term, even if it lowers them in the short term. It can also significantly hurt patients. This is because doctors may have very good reasons for prescribing particular drugs for specific patients. In such cases, individuals forced to take different medications can suffer severe side effects, complications and health deterioration.

For example, Eitan Kling-Levine, an ulcerative colitis patient, was required to take several drugs that were ineffective for him during a six-month period before getting his physician’s chosen therapy approved. During this time, his disease progressed to such an extent that his colon had to be surgically removed.

Kathleen Arntsen, a glaucoma patient, believes that she lost her vision in one eye because of step therapy. She had to try two different drugs over seven weeks before being allowed to switch to the more expensive Travatan Z eye drops that her physician initially prescribed. Others suffer unrelieved pain, depression and other symptoms because of step therapy constraints.

Imprecise medicine?

Step therapy is a one-size-fits-all approach to treatment. This is contrary to contemporary precision medicine research initiatives. Precision medicine refers to tailoring treatments to individuals with particular characteristics. It aims to enable doctors to select the right treatment for patients based on their symptoms, genetic makeup or other attributes. Step therapy policies that dictate which drugs all patients must take first could be a major hindrance to implementing precision medicine findings.

In addition, step therapy requirements can come as an unpleasant surprise to doctors and patients. Health insurers do not publicize their step therapy policies, and they can be difficult to locate on health insurers’ websites. Unexpected coverage rejections can cause treatment delays, exacerbating patients’ health problems.

Step therapy regulation

Some states have addressed step therapy through legislation. Eighteen states have enacted laws that regulate the practice, and several others have pending proposed bills.

None of these statutes completely bars step therapy. Instead, they limit it in a variety of ways.

For example, doctors may request that step therapy be waived for particular patients for medical reasons, and many laws require insurers to approve or deny such requests within 72 hours. The laws also instruct that waiver requests must be approved for patients who are already doing well on their doctors’ drug of choice. Exemptions must also be given for those who have previously tried the insurer’s preferred drug and found it to be ineffective or intolerable. Such provisions can be particularly beneficial for individuals whose employers switched to a new insurance plan that suddenly places new step therapy demands on them.

Still other laws strictly limit the duration of step therapy protocols to 30 or 60 days. If the trial period ends and the insurer’s mandated treatment has failed, the doctor’s drug of choice must be approved.

Step therapy statutes protect many patients. However, only a minority of states have them. Moreover, a federal law called ERISA makes state statutes that regulate insurance inapplicable to self-funded insurance plans. If your employer pays for medical claims out of its own pocket, it has a self-funded plan, though it may contract with an insurer to administer the plan. Experts estimate that over 60 percent of workers are enrolled in self-funded plans. Therefore, step therapy statutes do not protect the majority of workers even in states that have them.

Medicare regulations offer seniors many of the safeguards that are available under state step therapy statutes. However, non-Medicare patients may be left at the mercy of health insurers. Federal law provides Americans with a right to appeal insurance decisions. However, the appeals process may be lengthy and cumbersome.

Potential solutions

So what should be done to protect patients subject to step therapy? As a first measure, I believe, based on my research and experience, that all states should pass step therapy statutes. In addition, federal laws that govern health insurance should include provisions that specifically address step therapy.

Third, insurers should improve transparency and provide easily accessible information to patients and clinicians about their step therapy programs. Finally, insurers should monitor and incorporate up-to-date scientific and financial evidence into their step therapy programs. Step therapy requirements should be updated to reflect precision medicine research findings.

They should also be adjusted if it becomes clear that particular requirements can harm patients and increase long-term costs.

Most importantly, if you disagree with an insurer’s decision to decline coverage for a treatment your doctor recommends, don’t hesitate to appeal. You have an absolute right to do so even if you are not covered by a state step therapy statute or Medicare regulations. You may have to call your physician repeatedly to make sure the insurer is contacted and the paperwork is completed. Doctors are very busy, and they don’t enjoy or get reimbursed for arguing with insurers. But persistence is worthwhile. Your health may depend on it.

  • ET PRO
  • Market Data

Market-moving news and views, 24 hours a day >

April 19 08:30 UTC Released

GRCbank C/A YY

Actual

-0.99 0

Forecast

Previous

-1.183 0

April 19 08:00 UTC Released

ITConsumer Confidence

Actual

110.5 %

Forecast

111.2 %

Previous

111.2 %

January 31 00:00 UTC 638472638472m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 31 00:00 UTC 638472638472m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 22 19:00 UTC 650292650292m

ARTrade Balance

Actual

Forecast

Previous

-1541 %

January 31 00:00 UTC 638472638472m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 22 19:00 UTC 650292650292m

ARTrade Balance

Actual

Forecast

Previous

-1541 %

January 31 00:00 UTC 638472638472m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 31 00:00 UTC 638472638472m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 31 00:00 UTC 638472638472m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.